The Early Diagnosis of Pulmonary Nodule Based on Multi-dimension Messages

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology500 enrolled

Overview

The researchers are aimed to investigate the early diagnosis of pulmonary nodule based on DNA, RNA, protein, metabolites through analyzing the serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and clinical characteristics.

By recruiting people with pulmonary nodules identified by CT scans, three groups are confirmed as the lung cancer group, the benign lung nodule group who are identified by pathological analysis, and the small lung nodule group that should be followed up. Then the serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Pulmonary Nodule, Solitary Lung; Node

Interventions

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.DIAGNOSTIC_TEST

The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: For lung cancer groups * (1) Patients diagnosed with lung cancer; * (2) Clear diagnosis by pathological examination to determine pathological type; * (3) Those aged 18-80 years old; * (4) For patients with newly diagnosed lung cancer, CT confirmed that the size of primary lung cancer is ≤ 3 cm; * (5) The patient or family member agrees to participate in the study and sign an informed consent form; * (6) No other serious cardiopulmonary diseases. For lung nodule * (1) Those aged 18-80 years; * (2) CT clear lung nodule size ≤ 3cm; * (3) 1-3cm pulmonary nodules confirmed by pathological diagnosis as non-lung cancer or other metastatic cancer patients or ≤1cm pulmonary nodules * (4) The patient or family member agrees to participate in the study and sign an informed consent form; * (5) No other serious cardiopulmonary diseases. Exclusion Criteria: * (1) Women who are breast-feeding, pregnant or preparing for pregnancy; * (2) Those who are allergic to allergies and multiple drugs; * (3) Combining severe primary diseases such as cardiovascular and cerebrovascular, liver, kidney, and hematopoietic system, as well as subjects with mental illness; * (4) concurrently infected; * (5) Those who participated in other clinical trials within three months.

Locations (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

RECRUITING

Outcomes

Primary Outcomes

Up-regulation of ctDNA

Time frame: the first day subjects are enrolled the outcome will be assessed

Central Contacts

jinshuo fan

CONTACT

+8615827367482 whxhfjs@hust.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.